GlassScriptPhysician profile
Paul S Larson
NPI 1619483799
$1,516.42
in general payments reported to CMS, 2019-2025
15 companies · $457 in 2025
The $457 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $21.42 · 2023: $211 · 2024: $827 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,495.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $294.21 | 2024-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Alnylam Pharmaceuticals INC. | $238.41 | 2025 | Amvuttra, Onpattro |
| Astrazeneca Pharmaceuticals LP | $217.12 | 2024-2025 | Andexxa, Farxiga |
| Cvrx, INC. | $208.33 | 2023-2025 | Barostim Neo System |
| Amgen INC. | $155.92 | 2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.92 | 2024-2025 | Jardiance |
| Pfizer INC. | $74.95 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.45 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $37.02 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $30.46 | 2024-2025 | Eliquis |
| United Therapeutics Corporation | $29.19 | 2024 | Tyvaso |
| Kestra Medical Technology Services, INC. | $21.50 | 2024 | Assure Wcd |
| Nuwellis, INC. | $19.38 | 2025 | Aquadex Smartflow Console |
| Actelion Pharmaceuticals US, INC. | $17.56 | 2025 | Uptravi |
| Scpharmaceuticals INC. | $16.00 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Larson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.